Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Feb 20, 2024 6:07pm
385 Views
Post# 35889820

RE:RE:RE:Next leg of the uptick from recent low

RE:RE:RE:Next leg of the uptick from recent low
Well CF it would appear you make a lot of typos and my only motive is to correct those who incorrectly pass information along to others such as you have done many times.
A New advancement with Roche you say, well that is different than when you said a New trial with Roche.
We already know it is just a continuation of the trial with expanded sites.
And you still did not address your error in reporting that Matt Coffey exercised 350k options but of course you say you don't mislead people, you just report wrong information or your take on it.
NO motives hear as I have been in this as long as you have and even though l have an issue with managment and admit it, I do not pass on wrong information.
Also you are suggesting the company is in disaster recovery mode, so exactly what are you trying to tell everyone here. It would appear your motives are clear as I have never suggested anything like this.
<< Previous
Bullboard Posts
Next >>